About the TAPUR Study
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. The study will provide approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies, catalogue the choice of genomic profiling test by clinical oncologists and learn about the utility of registry data to develop hypotheses for additional clinical trials. To find responses to commonly asked questions, please visit our FAQ page and review our patient brochure.
Study participants get access to targeted drugs matched to the genomic profiles of their tumors.
Physician investigators receive assistance interpreting genomic test results and identifying appropriate treatments.
Cancer community learns about new uses of targeted anti-cancer drugs for patients who have exhausted current options.
Pharmaceutical companies get data on use of drugs for possible new cancer indications already being used in clinical practice.
Regulators get data about adverse events and other outcomes.
TAPUR Study News
ASCO has begun recruiting patients with advanced cancer for its first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) study. The trial will evaluate molecularly-targeted cancer drugs and collect data on clinical outcomes to help learn additional uses of these drugs outside of indications already approved by the Food and Drug Administration (FDA). Patients enrolled in the study will have access to these cancer drugs at no cost.
The American Society of Clinical Oncology announces its first-ever clinical trial, the TAPUR study. The TAPUR study aims to learn from patients with advanced cancer who lack standard treatment options.
An article from the Los Angeles Times discusses how innovative clinical trials, such as the TAPUR study, supports precision or personalized medicine that aims to improve the outcomes of cancer patients.
Network of Centers
TAPUR will launch in the first quarter of 2016 at four cancer center networks: the Carolinas HealthCare System's Levine Cancer Institute, the Cancer Research Consortium of West Michigan, the Michigan Cancer Research Consortium, and the University of Michigan with plans for expansion in late 2016.